FDA Losing Credibility With Public, Own Staff

BY JOEL B. FINKELSTEIN
Contributing Writer

WASHINGTON — Members of the scientific community have raised a red flag over the apparent increasing influence of money and politics on what are supposed to be the independent, unbiased internal workings of the Food and Drug Administration and other federal watchdog agencies.

In a recent confidential survey of staff scientists in the FDA’s Center for Drug Evaluation and Research, 19% reported being pressured to push through a drug about which they had reservations and 60% said that they were less than wholly confident that the FDA adequately monitors the safety of drugs before they hit the market.

Across the agency, 50% of respondents said they did not believe that the FDA was headed in the right direction, according to the survey by the Union of Concerned Scientists and Public Employees for Environmental Responsibility.

In the words of one staff scientist: “The FDA is presently being stacked at every management level, including the lowest levels, based on those who will support the big companies’ agenda, and the implications for safety and efficacy will be felt long after that drug is on the market.”

Such influences have led to a “crisis in public confidence,” according to Dr. Steven Nissen, who until last year chaired the FDA’s Cardiovascular and Renal Drugs Advisory Committee.

“We have to work a lot harder now . . . to keep the politicians out of the science as much as possible and to keep the commercialization of science from coloring everything we see and hear of scientific practice,” he said at a panel discussion about conflict of interest on government science panels sponsored by the Center for Science in the Public Interest. CSPI is a nonprofit consumer organization focused on food, nutrition, and health issues; it is perhaps best known for its efforts to disclose the nutritional content of fast-food products.

Dr. Nissen criticized the agency’s top leaders for “whining incessantly” to Congress about the burden of regulation rather than asking for more authority.

“While the American people worry about the safety of drugs, the top FDA leadership tells us we need fast drug approval,” he said.

The appointments of Lester Crawford, D.V.M., Ph.D., and Dr. Andrew von Eschenbach as acting FDA commissioner and Dr. Scott Gottlieb as deputy commissioner for policy also have raised some troubling questions about conflict of interest with the agency, Dr. Nissen said.

(“Dr. Crawford eventually gained Senate confirmation to his position, but resigned shortly thereafter.”)

“In his role as director of the National Cancer Institute, [acting commissioner von Eschenbach] must seek FDA approval for human testing or approval of new cancer drugs, an obvious conflict of interest. Even worse, the administration has appointed Scott Gottlieb as deputy commissioner, who came to this job with no regulatory experience, directly from Wall Street where he served as a biotech analyst and stock promoter,” Dr. Nissen said.

Also speaking as part of the panel, Dr. Gottlieb refused to address those charges, but defended FDA policy that allows the agency leeway in impaneling advisory committee members who have financial ties to industry.

The advice the FDA receives from advisory committee members must span the breadth of both clinical research and clinical practice, he said. “That’s the kind of advice that you can only get from people who are heavily engaged in clinical trials.”

Gottlieb also announced FDA plans to revamp the advisory committee guidelines, including updated rules that determine whether members need to be recused from a potential conflict of interest. However, it is unclear how those changes will relieve the concern, both inside and outside the agency, that these panels are being manipulated.

“I’ve observed that [FDA] management and [device and drug manufacturing] companies have found ways to manipulate this process in favor of approval. These methods are very subtle and would not easily be recognized,” recounted one respondent to the survey by the Union of Concerned Scientists. The anonymous respondent went on to describe these techniques.

“Within the FDA, scheduling conflicts can be used to exclude a committee member who is expected to oppose a drug’s approval,” he said.

Advise Patients Carefully on Medicare Part D Benefit Choices

PHILADELPHIA — Physicians can help Medicare beneficiaries who are trying to select a Medicare drug coverage plan, but they have to make sure they follow all the rules, Charlene L. McGinty said at the annual meeting of the American Health Lawyers Association.

The drug benefit, also known as Part D, was passed by Congress in 2003 and became effective in January 2006. Patients pay an annual deductible of $250 as well as a premium of about $37 per month, depending on the plan they choose. The plan then pays 75% of drug costs until the patient has spent $2,250. After that, in most plans, the patient has to pay the next $1,850 out of pocket; this period is known as the “doughnut hole” or “coverage gap.”

Once the beneficiaries’ bills hit $5,100, the plan pays 95% of any remaining costs for the rest of the year. High-income beneficiaries receive a more generous benefit.

Drug plans are administered by private insurers, but of the plans participating, 20 plans represent 90% of the market, said Ms. McGinty, who is with the program integrity group at the Centers for Medicare and Medicaid Services. But trying to help a patient get a drug for an off-label use not listed in the new drugs coming on the model formulary, but added that each plan’s pharmacy and therapeutics committee is supposed to be keeping tracking of new drug approvals and deciding whether to add a new drug.

Off-Label Drug Use

Plans are supposed to approve off-label use as long as the use is listed in one of three drug compendia, said Greg Jones, who is with the program integrity group at the Centers for Medicare and Medicaid Services. But trying to help a patient get a drug for an off-label use not listed in a compendium will be a “troublesome” problem for doctors, he conceded.

Although providers can give patients some help in choosing a drug plan—and even help low-income beneficiaries fill out the paperwork to get better benefits—“tension exists because there are limitations on what providers can say about various drug plans, Ms. McGinty explained. For example, providers cannot make specific plan recommendations, they can’t steer an undeclared enrollee to one plan over another, and they can’t accept plan applications.